
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is showing strong potential as a biopharmaceutical company, with a proven track record in producing effective anti-SARS-CoV-2 antibodies, such as PEMGARDA, and a highly differentiated and potent next-generation antibody, VYD2311, in development. With a potential market availability in 2027, early feedback from stakeholders has been favorable, and reimbursement pushback has been minimal for existing products, indicating strong market potential. Additionally, the company's focus on single-dose administration and a flexible multidose option for higher-risk periods may improve commercial viability and accessibility. Overall, Invivyd is well-positioned to drive success in multiple infectious disease targets, and investors may be underestimating the potential of its products.
Bears say
Invivyd is currently conducting clinical trials for its lead product PEMGARDA, with potential commercialization in 2027. However, the success of this product and subsequent BLA submission depends heavily on the results of the DECLARATION and LIBERTY trials, with potential risks including unexpected outcomes and regulatory uncertainty. Additionally, the company faces risks in the increasingly complex and price-sensitive commercial market for biopharmaceuticals.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares